A detailed history of Murphy, Middleton, Hinkle & Parker, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Murphy, Middleton, Hinkle & Parker, Inc. holds 8,145 shares of BMY stock, worth $450,255. This represents 0.23% of its overall portfolio holdings.

Number of Shares
8,145
Previous 8,478 3.93%
Holding current value
$450,255
Previous $352,000 19.6%
% of portfolio
0.23%
Previous 0.2%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$39.66 - $51.75 $13,206 - $17,232
-333 Reduced 3.93%
8,145 $421,000
Q1 2024

Apr 11, 2024

SELL
$47.98 - $54.4 $8,588 - $9,737
-179 Reduced 2.07%
8,478 $459,000
Q1 2023

Apr 05, 2023

BUY
$65.71 - $74.53 $21,881 - $24,818
333 Added 4.0%
8,657 $600,000
Q3 2022

Oct 07, 2022

BUY
$0.13 - $76.84 $0 - $230
3 Added 0.04%
8,324 $592,000
Q1 2022

Apr 14, 2022

SELL
$61.48 - $73.72 $3,688 - $4,423
-60 Reduced 0.72%
8,321 $608,000
Q2 2021

Jul 13, 2021

BUY
$61.91 - $67.42 $8,295 - $9,034
134 Added 1.62%
8,381 $560,000
Q4 2020

Jan 12, 2021

SELL
$57.74 - $65.43 $26,560 - $30,097
-460 Reduced 5.28%
8,247 $512,000
Q2 2020

Jul 08, 2020

BUY
$54.82 - $64.09 $493 - $576
9 Added 0.1%
8,707 $512,000
Q1 2020

Apr 09, 2020

SELL
$46.4 - $67.43 $5,336 - $7,754
-115 Reduced 1.3%
8,698 $485,000
Q4 2019

Jan 08, 2020

BUY
$49.21 - $64.19 $91,284 - $119,072
1,855 Added 26.66%
8,813 $566,000
Q1 2019

Apr 17, 2019

BUY
$45.12 - $53.8 $9,024 - $10,760
200 Added 2.96%
6,958 $332,000
Q2 2018

Jul 13, 2018

BUY
$50.53 - $62.98 $341,481 - $425,618
6,758 New
6,758 $374,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $118B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Murphy, Middleton, Hinkle & Parker, Inc. Portfolio

Follow Murphy, Middleton, Hinkle & Parker, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Murphy, Middleton, Hinkle & Parker, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Murphy, Middleton, Hinkle & Parker, Inc. with notifications on news.